AVAI
Avai Bio, Inc.·Technology
0.32
1.250%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.2652W H: $0.83
AVAI NEWS
prnewswire.com
1d ago
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
prnewswire.com
4d ago
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
LAS VEGAS, April 7, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual Klotho Conference, which focuses on the future of Klotho-based therapies.
prnewswire.com
Mar 27
Scalable Biotech Manufacturing Unlocks a $14B Market
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
accessnewswire.com
Mar 17
Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
KELOWNA, BC / ACCESS Newswire / March 17, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of ultra-premium cannabis products, today announced that its wholly-owned subsidiary, GreenTec Holdings Ltd. ("GreenTec"), has issued a formal notice of termination for its Trademark Licensing Agreement with Adjupharm GmbH ("Adjupharm"), a subsidiary of IM Cannabis Corp. The Agreement was originally announced on May 1, 2024.
accessnewswire.com
Mar 9
Avant Brands Continues to Strengthen Balance Sheet with $1.77 Million Debt Retirement at $0.935 Per Unit
KELOWNA, BC / ACCESS Newswire / March 9, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), is pleased to announce that it has entered into a debt settlement agreement (the "Agreement") with an institutional investor (the "Creditor") to retire a significant portion of the Company's largest remaining debt obligation (the "Transaction"). The Transaction, which is expected to close during the month of March, will extinguish approximately $1.77 million of the Company's amended and restated unsecured convertible debenture (the "Debenture") through the issuance of 1,900,000 units (each a "Unit", more fully defined below) at a deemed price of $0.935 per Unit, representing a premium to the current market price of the Company's common shares (each a "Share").
prnewswire.com
Mar 3
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical
